Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole

Frucht, Steven J.; Rogers, Jennifer; Greene, Paul; Gordon, Mark Forrest; Fahn, Stanley

doi:10.1212/wnl.52.9.1908

Cited by 647 publications

(346 citation statements)

References 5 publications

Supporting

Mentioning

307

Contrasting

Unclassified

Order By: Relevance

“…70 The dopamine agonists, bromocriptine, and pramipexole, as well as L-dopa, have been reported to cause excessive daytime sleepiness. 71,72 Patients should be informed of the potential sedative side effects of dopaminergic medication and its implication on safe driving.…”

Section: Medication Related Effectsmentioning

confidence: 99%

Neurologic Conditions: Assessing Medical Fitness to Drive

Yale¹,

Hansotia²,

Knapp³

et al. 2003

Clinical Medicine & Research

View full text Add to dashboard Cite

Clinicians are often asked to make an assessment on whether a patient is medically fit to drive, even though few have been formally trained in this area. Driving is a complex task that requires having adequate operational, cognitive and higher executive functions that work together. These functions can be compromised to a greater or lesser extent in neurological disorders, such as stroke, traumatic brain injury, peripheral neuropathy, dementia, Parkinson's disease and epilepsy. There is insufficient standardized information relating to impaired function at this time. Because of this, state laws vary in their assessment of medical conditions as they relate to driver licensing. Wisconsin laws are reviewed as an example. There are numerous assessment tests for various functions, but they lack a validated correlation with actual driving performance. These and other factors, as well as practical recommendations for the practicing physicians, are the subjects of this review.

show abstract

Section: Medication Related Effectsmentioning

confidence: 99%

Neurologic Conditions: Assessing Medical Fitness to Drive

Yale¹,

Hansotia²,

Knapp³

et al. 2003

Clinical Medicine & Research

View full text Add to dashboard Cite

show abstract

“…It was not until 1999, however, after Frucht et al 70 reported that eight patients with PD had fallen asleep at the wheel, that concerns about sleep attacks arose. Seven of the eight patients were taking pramipexole, and it was suggested that this drug was the cause.…”

Section: Phase III Clinical Trial Results In Advanced Patientsmentioning

confidence: 99%

“…71,72 These reports engendered an unusual amount of interest, response, and controversy. 72,73 Based on the report by Frucht et al, 70 the FDA and health organizations around the world required amendments to package inserts, including a black box warning in the United States with a statement that patients should not drive until "they have gained sufficient experience with [pramipexole] to gauge whether or not it affects their mental and/or motor performance adversely. "…”

Section: Phase III Clinical Trial Results In Advanced Patientsmentioning

confidence: 99%

Current Status of Symptomatic Medical Therapy in Parkinson’s Disease

Factor

2008

Neurotherapeutics

View full text Add to dashboard Cite

Summary: Symptomatic medical therapies for Parkinson's disease (PD) have been disease modifying and have led to improvement in daily function, quality of life, and survival. For 40 years, these therapies have been primarily dopaminergic, and currently include the dopamine (DA) precursor levodopa (LD), DA agonists, catechol-O-methyltransferase (COMT) inhibitors, and monoamine oxidase (MAO) inhibitors. The roles of all these classes of agents have evolved, with significant changes occurring since the early 2000s. This article reviews the current literature for each of these classes of drugs, with a focus on efficacy and place in the therapeutic scheme. Levodopa is no longer considered to be toxic and, thus, its early use is not only appropriate but recommended.Ergot agonists are no longer in use, and new agents administered in patch form or subcutaneous injections have been approved. The COMT inhibitor tolcapone, with its significant efficacy, has been reintroduced, and two new MAO inhibitors have been approved. Selected safety issues are discussed, including the incidence of melanoma in relation to LD; pathological gambling and DA agonists; hepatic toxicity of tolcapone; and the tyramine or so-called cheese reaction with MAO B inhibitors. The article closes with a discussion of future directions and new drugs under development.

show abstract

“…7 Nausea, dizziness and insomnia are similar between the two therapies. Sudden attacks of sleepiness resulting in motor vehicle accidents have been reported since approval, 25 leading to a warning on the label. Additional label changes since approval include warnings concerning pathological gambling and other impulse control disorders (ICD).…”

Section: Monotherapy With Ropinirole Immediate Releasementioning

confidence: 99%

Update on ropinirole in the treatment of Parkinson’s disease

Shill

Stacy

2008

NDT

View full text Add to dashboard Cite

Ropinirole is a dopamine agonist, approved for use to treat symptoms of early and advanced Parkinson's disease, is now available in a 24-hour formulation in addition to the immediate release version. This review discusses the mode of action of ropinirole and compares the pharmacokinetics of both formulations. Pivotal studies leading to the approval of both preparations are reviewed in terms of effi cacy, dose range and side effects. Patient factors such as compliance are discussed in terms of the place for ropinirole in the armamentarium of Parkinson's disease therapies.

show abstract

Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole

Cited by 647 publications

References 5 publications

Neurologic Conditions: Assessing Medical Fitness to Drive

Neurologic Conditions: Assessing Medical Fitness to Drive

Current Status of Symptomatic Medical Therapy in Parkinson’s Disease

Update on ropinirole in the treatment of Parkinson’s disease

Contact Info

Product

Resources

About

Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole

Cited by 647 publications

References 5 publications

Neurologic Conditions: Assessing Medical Fitness to Drive

Neurologic Conditions: Assessing Medical Fitness to Drive

Current Status of Symptomatic Medical Therapy in Parkinson’s Disease

Update on ropinirole in the treatment of Parkinson&rsquo;s disease

Contact Info

Product

Resources

About

Update on ropinirole in the treatment of Parkinson’s disease